1. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study.
- Author
-
Osama Gaber, A., Mulgaonkar, Shamkant, Kahan, Barry D., Steve Woodle, E., Alloway, Rita, Bajjoka, Iman, Jensik, Stephen, Klintmalm, Goran B., Patton, Pamela R., Wiseman, Alexander, Lipshutz, Gerald, Kupiec-Weglinski, Jerzy, Gaber, Lilian W., Katz, Eliezer, Irish, William, Squiers, Elizabeth C., and Hemmerich, Stefan
- Subjects
HOMOGRAFTS ,KIDNEY physiology ,BLIND experiment ,PLACEBOS ,MEDICAL centers ,IMMUNOGLOBULIN G ,GLYCOPROTEINS - Abstract
Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway R, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: A double-blind, placebo-controlled, multi-center Phase IIa study. Clin Transplant 2011: 25: 523-533. © 2010 John Wiley & Sons A/S. Abstract: Introduction: Recombinant P-selectin glycoprotein ligand IgG fusion protein, rPSGL-Ig (YSPSL), a fusion protein of human P-selectin ligand and IgG1-Fc, blocks leukocyte adhesion and protects against ischemia reperfusion injury (IRI) in animal models. Patients and Methods: This randomized 15-center, double-blind, 59-patient Ph2a study assessed YSPSL's safety in recipients of deceased-donor kidney allografts and its potential efficacy in improving early graft function. Two doses and two dosing modalities were evaluated. Results: No drug-specific toxicities or increased adverse event rates were noted. Two YSPSL-treated patients died of causes determined as unrelated to study drug. YSPSL did not reduce the incidence of dialysis within the first week post-transplant (41% in treated vs. 20% in placebo patients). Renal function endpoints scored at post-operative days 1 & 2 were also not impacted by YSPSL. However, at day 5, the fraction of patients with serum creatinine above 6 mg/dL was lower in the YSPSL vs. placebo group (26% vs. 55%, p = 0.043). Large variations in the dialysis-delayed graft function (DGF) rates were observed between centers, independently of treatment assignment, indicating subjectivity of this endpoint. Conclusion: In this first Ph2a study in kidney transplantation, YSPSL was safe but did not impact the dialysis-DGF rate. Further studies with more objective efficacy endpoints are required to define the impact of YSPSL on early renal allograft function. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF